Ara-C fever and infections after high-dose Ara-C treatment in pediatric lymphoid malignancies

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 7, 2005, Pages 364-369

  Ek, Torben ^a,b   Pinkava, Mirka ^a   Abrahamsson, Jonas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Ara C; Fever; Lymphopenia; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; C REACTIVE PROTEIN; CORTICOSTEROID; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; ONDANSETRON; PREDNISOLONE; PROCALCITONIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALPHA HEMOLYTIC STREPTOCOCCUS; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEVER; HUMAN; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTICEMIA; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEVER; HUMANS; INFANT; INFECTION; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 23044514986     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000173176.33271.8f     Document Type: Conference Paper

References (27)

1. Estlin EJ, Yule SM, Lowis SP. Consolidation therapy for childhood acute lymphoblastic leukemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. Cancer Treat Rev. 2001;27:339-350.
2. Barrios NJ, Tebbi CK, Freeman AI, et al. Toxicity of high-dose Ara-C in children and adolescents. Cancer. 1987;60:165-169.
3. Castleberry RP, Crist WM. Holbrook T, et al. The cytosine arabinoside (Ara-C) syndrome. Med Pediatr Oncol. 1981;9:257-264.
4. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999;18:875-881.
5. Fleischhack G, Kambeck I. Cipic D, et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol. 2000;111: 1093-1102.
6. Lex C, Korholz D, Kohlmuller B, et al. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma: a rationale for tailored supportive care. Support Care Cancer. 2001;9: 514-521.
7. Bochud PY, Eggiman P, Calandra T, et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25-31.
8. Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25:696-703.
9. Paganini H, Staffolani V, Zubizarreta P, et al. Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors. Eur J Cancer. 2003;39:1284-1289.
10. Shenep JL. Viridans-group streptococcal infections in immunocompromised hosts. Int J Antimicrob Agents. 2000;14:129-135.
11. Ek T, Jarfelt M, Mellander L, et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol. 2001;37:459-464.
12. Meisner M. Procalcitonin (PCT). Rottenburg: Georg Thieme Verlag, 2000.
13. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J. 2000;19:679-688.
14. Bernard L, Fernere F, Casassus P, et al. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis. 1998;27:914-915.
15. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 1996;40:1108-1115.
16. Rose MS, Bateman DN. Pyrexia with cytosine arabinoside. Br Med J. 1972;4:115.
17. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004;10:201-222.
18. Brach MA, Kharbanda SM, Herrmann F, et al. Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1 -beta-D-arabinofuranosylcytosine. Mol Pharmacol. 1992;41:60-63.
19. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283-286.
20. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274:782-784.
21. Oberhoffer M, Stonans I, Russwurm S, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999; 134:49-55.
22. Dornbusch HJ, Strenger V, Kerbl R, et al. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and gram-negative sepsis. Bone Marrow Transplant. 2003;32: 941-945.
23. Schuttrumpf S, Binder L, Hagemann T, et al. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98-103.
24. Chen SH, Liang DC, Liu HC. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia. Am J Hematol. 1998;58:20-23.
25. Saarinen-Pihkala UM, Lanning M, Perkkio M, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol. 2000;34: 319-327.
26. Hofmann WK, Seipelt G, Langenhan S, et al. Prospective randomized trial to evaluate two delayed granulocyte colony-stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol. 2002;81: 570-574.
27. Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996; 14:636-643.